livtencity

Generic: maribavir

Labeler: takeda pharmaceuticals america, inc.
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name livtencity
Generic Name maribavir
Labeler takeda pharmaceuticals america, inc.
Dosage Form TABLET, COATED
Routes
ORAL
Active Ingredients

maribavir 200 mg/1

Manufacturer
Takeda Pharmaceuticals America, Inc.

Identifiers & Regulatory

Product NDC 64764-800
Product ID 64764-800_14acb19d-0258-47df-a01a-bdca1ea05e54
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA215596
Listing Expiration 2027-12-31
Marketing Start 2021-11-23

Pharmacologic Class

Established (EPC)
cytomegalovirus pul97 kinase inhibitor [epc]
Mechanism of Action
cytomegalovirus pul97 kinase inhibitors [moa] cytochrome p450 3a4 inhibitors [moa] p-glycoprotein inhibitors [moa] breast cancer resistance protein inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 64764800
Hyphenated Format 64764-800

Supplemental Identifiers

RxCUI
2586073 2586079
UNII
PTB4X93HE1
NUI
N0000193976 N0000193977 N0000182141 N0000185503 N0000190113

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name livtencity (source: ndc)
Generic Name maribavir (source: ndc)
Application Number NDA215596 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 200 mg/1
source: ndc
Packaging
  • 1 BOTTLE in 1 CARTON (64764-800-28) / 28 TABLET, COATED in 1 BOTTLE
  • 1 BOTTLE in 1 CARTON (64764-800-56) / 56 TABLET, COATED in 1 BOTTLE
source: ndc

Packages (2)

64764-800-28 1 BOTTLE in 1 CARTON (64764-800-28) / 28 TABLET, COATED in 1 BOTTLE 64764-800-56 1 BOTTLE in 1 CARTON (64764-800-56) / 56 TABLET, COATED in 1 BOTTLE

Ingredients (1)

maribavir (200 mg/1)

Linked Drug Pages (1)

Livtencity ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "14acb19d-0258-47df-a01a-bdca1ea05e54", "openfda": {"nui": ["N0000193976", "N0000193977", "N0000182141", "N0000185503", "N0000190113"], "unii": ["PTB4X93HE1"], "rxcui": ["2586073", "2586079"], "spl_set_id": ["c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0"], "pharm_class_epc": ["Cytomegalovirus pUL97 Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Cytomegalovirus pUL97 Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 BOTTLE in 1 CARTON (64764-800-28)  / 28 TABLET, COATED in 1 BOTTLE", "package_ndc": "64764-800-28", "marketing_start_date": "20211123"}, {"sample": false, "description": "1 BOTTLE in 1 CARTON (64764-800-56)  / 56 TABLET, COATED in 1 BOTTLE", "package_ndc": "64764-800-56", "marketing_start_date": "20211123"}], "brand_name": "Livtencity", "product_id": "64764-800_14acb19d-0258-47df-a01a-bdca1ea05e54", "dosage_form": "TABLET, COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytomegalovirus pUL97 Kinase Inhibitor [EPC]", "Cytomegalovirus pUL97 Kinase Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "64764-800", "generic_name": "MARIBAVIR", "labeler_name": "Takeda Pharmaceuticals America, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Livtencity", "active_ingredients": [{"name": "MARIBAVIR", "strength": "200 mg/1"}], "application_number": "NDA215596", "marketing_category": "NDA", "marketing_start_date": "20211123", "listing_expiration_date": "20271231"}